I agree Our site saves small pieces of text information (cookies) on your device in order to deliver better content and for statistical purposes. You can disable the usage of cookies by changing the settings of your browser. By browsing our website without changing the browser settings you grant us permission to store that information on your device.
2-Methyl-6-(trifluoromethyl)nicotinic acid is used as a pharmaceutical intermediate.
Kirk D. Robarge.; Shirley A. Brunton.; Georgette M. Castanedo.; Yong Cuia, Michael S. Dina.; Richard Goldsmith.; Stephen E. Gould.; Oivin Guichert.; Janet L. Gunzner.; Jason Halladay.; Wei Jia.; Cyrus Khojasteh.; Michael F.T. Koehlera, Karen Kotkowc, Hank Laa, Rebecca L. LaLondea, Kevin Lau.; Leslie Lee.; Derek Marshall.; James C. Marsters Jr.; Lesley J. Murray.; Changgeng Qian.; Lee L. Rubin.; Laurent Salphati.; Mark S. Stanley.; John H.A. Stibbard.; Daniel P. Sutherlin.; Savita Ubhayaker.; Shumei Wang.; Susan Wong.; Minli Xie. GDC-0449A potent inhibitor of the hedgehog pathway. Bioorganic & Medicinal Chemistry Letters. 2009, 19 (19), 5576-5581.
Gefahrenhinweise (EU): H315-H319-H335
Causes skin irritation. Causes serious eye irritation. May cause respiratory irritation.
Avoid breathing dust/fume/gas/mist/vapours/spray. Wear protective gloves and eye/face protection. IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. IF INHALED: Remove to fresh air and keep at rest in a position comfortable for breathing. Store locked up. Dispose of contents/container in accordance with local/regional/national/international regulations.